Approval
China Approves Hengrui ANGPTL3 Antibody
China approved Hengrui's ANGPTL3 antibody 艾轻达 for use alongside a low-fat diet and other lipid-lowering drugs in adults and adolescents aged 12 or older with homozygous familial hypercholesterolemia. In the phase 3 SHR-1918-301 trial, the treatment reduced LDL cholesterol by 64.2% relative to placebo at week 12; 88.9% of treated patients achieved at least a 50% reduction from baseline at week 24.
The drug is administered as a 600 mg subcutaneous injection every four weeks. Additional indications remain in clinical development.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.